Compare Arctoris vs Recursion
Customers evaluate the quality of Arctoris's products using the following success metrics.
Arctoris is 8 yrs old and is based in United Kingdom.
Arctoris develops an automated drug discovery company. It combines its unique automation platform, Ulysses, with advanced machine learning approaches and a team of seasoned drug hunters to guide and progress drug discovery programs in oncology and neurology. It offers on-demand access to various drug discovery assays conducted by robotics to biotech companies, pharmaceutical corporations, and academic centers. It was founded in 2016 and is based in Oxfordshire, United Kingdom.
Recursion is 11 yrs old and is based in United States.
Recursion (NASDAQ: RXRX) is a clinical-stage biotechnology company. It develops drugs for a variety of diseases, including Alzheimer's, cancer, and rare diseases. The company was founded in 2013 and is based in Salt Lake City, Utah.
Why Arctoris beats Recursion
Information not available because Recursion has not claimed their profile.
Work for Recursion? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Recursion?
Claim your profile now.
- data quality
- speed of data generation
Biotech and pharma companies use our technology platform and expert team to progress their R&D better and faster.
Why They Buy
News & Analysis
Arctoris has been mentioned in our research 1 time.
Recursion has been mentioned in our research 8 times.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Winners of CB Insights' annual AI 100, a list of the 100 most promising AI startups in the world.
HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare
ESP Rankings position vendors based on their resources and execution.
Arctoris is a Leader in AI oncology drug development
The AI oncology drug development market leverages artificial intelligence and machine learning techniques to analyze vast amounts of genomic, proteomic, and clinical data, enabling more precise identification of therapeutic targets, prediction of drug responses, and optimization of treatment regimens. AI solutions in oncology drug development help researchers accelerate the discovery of novel compounds, design more effective clinical trials, and improve patient stratification for personalized medicine. By harnessing the power of AI, this market aims to enhance the efficiency and success rate of drug discovery and development, ultimately leading to the delivery of safer, more targeted, and potentially life-saving oncology treatments.